246 related articles for article (PubMed ID: 17274384)
1. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
[No Abstract] [Full Text] [Related]
2. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
3. Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Oncologic Drugs Advisory Committee
Clin Colorectal Cancer; 2002 May; 2(1):8-10. PubMed ID: 12453328
[No Abstract] [Full Text] [Related]
4. Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Chico IM; Pazdur R
Clin Colorectal Cancer; 2002 May; 2(1):11-2. PubMed ID: 12453329
[No Abstract] [Full Text] [Related]
5. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Pestalozzi BC
N Engl J Med; 2001 Jan; 344(4):306; author reply 306-7. PubMed ID: 11191662
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
7. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
[No Abstract] [Full Text] [Related]
8. [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Motomura S
Nihon Rinsho; 2003 Sep; 61 Suppl 7():360-3. PubMed ID: 14574913
[No Abstract] [Full Text] [Related]
9. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Douillard JY; Cunningham D; Roth AD; Navarro M; James RD; Karasek P; Jandik P; Iveson T; Carmichael J; Alakl M; Gruia G; Awad L; Rougier P
Lancet; 2000 Mar; 355(9209):1041-7. PubMed ID: 10744089
[TBL] [Abstract][Full Text] [Related]
11. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Alimonti A; Satta F; Pavese I; Burattini E; Zoffoli V; Vecchione A
Ann Oncol; 2003 May; 14(5):805-6. PubMed ID: 12702539
[No Abstract] [Full Text] [Related]
12. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
14. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Klautke G; Fietkau R
Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
[No Abstract] [Full Text] [Related]
15. A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.
Mross K; Büchert M; Fasol U; Jaehde U; Kanefendt F; Strumberg D; Arends J; Hense J; Moritz B; Fischer R; Scheulen ME
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):96-8. PubMed ID: 21176744
[No Abstract] [Full Text] [Related]
16. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
[No Abstract] [Full Text] [Related]
18. Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.
Shimada S; Yagi Y; Shiomori K; Kuramoto M; Aoki N; Ogawa M
Oncol Rep; 2002; 9(4):783-7. PubMed ID: 12066209
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
